この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2012/2/271 分で読めます
Final Decision on Withdrawal of Breast Cancer Indication for AVASTIN (Bevacizumab) Following Public Hearing; Availability
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is announcing the availability of the final decision withdrawing approval of the breast cancer indication for AVASTIN (Bevacizumab). The Commissioner of Food and Drugs (the Commissioner) issued the decision following a June 2011 public hearing on a proposal to withdraw the approval.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →